

BioCardia, Inc.  
Form 8-K  
November 14, 2018

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):**

**November 12, 2018**

---

**BioCardia, Inc.**

(Exact name of registrant as specified in its charter)

---

Delaware                      0-21419                      23-2753988  
(State or Other Jurisdiction of    (Commission File Number) (I.R.S. Employer

Edgar Filing: BioCardia, Inc. - Form 8-K

Incorporation or Organization)

Identification Number)

125 Shoreway Road, Suite B

San Carlos, CA 94070

(Address of principal executive offices, including zip code)

(650) 226-0120

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events.**

On November 12, 2018, BioCardia, Inc. (the “Company”) issued a press release announcing that positive 12-month data from the 10 patient roll-in cohort of the Company’s Phase III pivotal CardiAMP heart failure trial were presented at the American Heart Association Scientific Sessions 2018 on November 12. A copy of the press release and presentation is attached hereto as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	<u>Press release dated November 12, 2018</u>
99.2	<u>American Heart Association Scientific Sessions Presentation, November 12, 2018.</u>

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 13, 2018

**BIOCARDIA, INC.**

By: /s/ Peter Altman

**Peter Altman**

*Chief Executive Officer*

*(Principal Executive Officer)*